No Data
Express News | The second half of the third day of medical insurance negotiations is about to begin! Companies like Shanghai Yizhong, China Resources, Bayer, etc. are participating.
Shanghai Yizhong: Report of Shanghai Yizhong Pharmaceutical Co., Ltd. for the third quarter of 2024
Shanghai Yizhong Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
Shanghai Yizhong (688091.SH) released its performance for the first three quarters, with a net income of 34.67 million yuan, a year-on-year decrease of 73.46%.
Shanghai Yizhong (688091.SH) disclosed its third quarter report for 2024, realizing operating income for the first three quarters...
Shanghai Yizhong (688091.SH): The net income for the first three quarters was 34.67 million yuan, a year-on-year decrease of 73.46%.
Geelong announced its third-quarter report on October 28th, with revenue of 0.17 billion yuan for the first three quarters, a year-on-year decrease of 39.25%, net income of 34.67 million yuan, a year-on-year decrease of 73.46%, non-GAAP net income of 31.08 million yuan, a year-on-year decrease of 72.39%, and basic earnings per share of 0.17 yuan.
Is being included in medical insurance a lifesaving straw? Shanghai Yizhong's core products cannot enter hospitals, investors inquire about the progress of national talks | Direct hitting earnings conference
①Due to the closure of the self-funded pharmacy for core hospital clients, shanghai Yizhong's self-funded product, Paclitaxel micelles not covered by medical insurance, cannot be admitted to hospitals, impacting its performance in the first half of the year. ②Shanghai Yizhong is preparing Paclitaxel micelles to participate in this year's medical insurance negotiation. In response to this, the director stated that the national medical insurance negotiation progress of Paclitaxel micelles is normal, and the final negotiation result will be subject to subsequent announcements.
No Data
No Data